FDA to review Acadia’s Nuplazid drug to treat Parkinson’s disease psychosis
The meeting will be held on 29th March. Last November, the FDA classified the Nuplazid NDA as having priority review status with a target prescription drug user fee
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.
Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with